Results 171 to 180 of about 37,814 (299)

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization Secondary to Endogenous Endophthalmitis [PDF]

, 2009
Shwu‐Jiuan Sheu
openalex   +1 more source

Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting

Clinical Ophthalmology, 2012
Angela M Carneiro,1,2 Luis S Mendonça,1 Manuel S Falcão,1,2 Sofia L Fonseca,1 Elisete M Brandão,1 Fernando M Falcão-Reis1,21Department of Ophthalmology of Hospital de São João, Porto ...
Carneiro AM, Mendonça LS, Falcão MS, Fonseca SL, Brandão EM, Falcão-Reis FM   +5 more
doaj  

Intravitreal ranibizumab (Lucentis®) in the treatment of retinal angiomatous proliferation (RAP) [PDF]

, 2009
Lazaros Konstantinidis, Evangelia Mameletzi, Irmela Mantel, Jean‐Antoine Pournaras, Léonidas Zografos, Aude Ambresin   +5 more
openalex   +1 more source

Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial

The Lancet, 2019
A. Stahl, D. Lepore, A. Fielder, B. Fleck, J. Reynolds, M. Chiang, Jun Li, Melissa Liew, Rainer Maier, Qixiong Zhu, N. Marlow   +10 more
semanticscholar   +1 more source

Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions

Clinical Ophthalmology, 2013
Michael A Singer,1 Steven R Cohen,2 Sylvia L Groth,3 Salman Porbandarwalla21Medical Center Ophthalmology Associates (MCOA), San Antonio, Texas, USA; 2Department of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio ...
Singer MA, Cohen SR, Groth SL, Porbandarwalla S   +3 more
doaj  

Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial

JAMA ophthalmology, 2018
N. Bressler, Wesley T Beaulieu, A. Glassman, K. Blinder, S. Bressler, L. Jampol, M. Melia, J. Wells   +7 more
semanticscholar   +1 more source

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab

Clinical Ophthalmology, 2016
Eric Nudleman,1 Jeremy D Wolfe,2,3 Maria A Woodward,4 Yoshihiro Yonekawa,2,3 George A Williams,2,3 Tarek S Hassan2,3 1Department of Ophthalmology, Shiley Eye Center, University of California, San Diego, La Jolla, CA, 2Beaumont Eye Institute, Oakland ...
Nudleman E, Wolfe JD, Woodward MA, Yonekawa Y, Williams GA, Hassan TS   +5 more
doaj  

Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study [PDF]

, 2010
Paisan Ruamviboonsuk, Mongkol Tadarati, Sumeth Vanichvaranont, Prut Hanutsaha, Nattapol Pokawattana   +4 more
openalex   +1 more source

PSS15 THE COST-EFFECTIVENESS OF RANIBIZUMAB (LUCENTIS®) IN TREATING PATIENTS WITH PREDOMINANTLY CLASSIC, MINIMALLY CLASSIC, AND OCCULT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD)

, 2008
Adam Turpcu, JW Hay
openalex   +1 more source

Sustainable Practices in Anti-VEGF Therapy: A 15-Year Bibliometric Analysis of Ranibizumab for Age-Related Macular Degeneration. [PDF]

J Ophthalmol
Xiaodong L, Xia C, Xuewei Q, Dandan W, Yi Y, Zhilin L.   +5 more
europepmc   +1 more source